Aurora Cannabis Inc vs Tripadvisor Inc Common Stock — how do they compare? Aurora Cannabis Inc trades at $3.45 (market cap $178.92M), while Tripadvisor Inc Common Stock trades at $10.89 (market cap $1.26B). The key difference: Tripadvisor Inc Common Stock is far larger — about 7× Aurora Cannabis Inc's market cap. Which is the better fit depends on your goals.
| ACB | TRIP | |
|---|---|---|
Market Cap | $178.92M | $1.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.23 | $19.14 |
52-Week Low | $2.58 | $9.24 |
Enterprise Value | $123.48M | $1.31B |
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.
ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.
Tripadvisor (TRIP) trades at $10.78, up 3.45% today, but faces bearish technical signals with recent earnings misses. The company maintains strong gross margins at 92.11% but struggles with thin net income margins of 0.27%. Recent Q2 2026 results missed expectations, though the $700M sale of TheFork to American Express provides strategic focus and cash infusion. Analyst consensus is mixed with 62.5% hold ratings and a $13.71 price target suggesting 27% upside potential from current levels.
TRIP presents a turnaround opportunity with simplified operations post-TheFork sale and Viator's growth potential, but faces persistent search-related pressures and uneven travel demand. The stock trades at reasonable valuations (P/S 0.7x) but carries execution risks amid competitive threats. Cash flow trends show volatility, with negative net cash flow projected for 2026, requiring careful monitoring of the company's strategic execution.
Trailing returns across standard periods
Latest headlines on both assets
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →